After Genentech, Roche could acquire another American Billion-dollar Biotech

11/07/2016 - 2 minutes

Roche is rumored to make a move on the California biotech BioMarin. Despite a slightly weakened pipeline, Roche appears undeterred and previous offers were predicted to be around $15Bn.

biomarin biotech rocheAs big as some of the other industry veterans, BioMarin was founded in the 90’s boom in Biotech in San Rafaele, California. The deal itself is entirely based on rumor and anonymous sources, originally appearing on the blog Betaville.

Nonetheless, after a similar move was also made by Roche in 2013 (up to a value of $15Bn!), the markets have still seen over a 10% jump in BioMarin’s stocks.

This is slightly surprising, as although 2016 was predicted to be a fortuitous year for the company, the pipeline and product development isn’t as strong as it could be.

In early 2015, BioMarin also acquired the Dutch biotech ProSensa in an impressive $840M, so rights to their proprietary exon-skipping RNA technology would also pass onto Roche. ProSensa’s tech also applications in neuromuscular diseases,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member